Chronic Inflammatory Demyelinating Polyradiculoneuropathy Clinical Trials

43 clinical trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — RECRUITING · PHASE3
• Biomarkers in Autoimmune Disease of Nervous System — RECRUITING
• A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP — RECRUITING · PHASE3
• Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study — RECRUITING
• A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — RECRUITING · PHASE2
• A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — RECRUITING · PHASE3
• Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases — RECRUITING · PHASE1
• A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care — RECRUITING
• Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic Findings and if This Method Aids Early Diagnosis, Predict Their Outcomes and Differentiate Between Axonal and Demyelinating Subtypes. — RECRUITING
• Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases — RECRUITING · PHASE1
• Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System — RECRUITING · PHASE1
• Evaluate efficacy and safety of fingolimod 0.5 mg orally once daily versus placebo in chronic inflammatory demyelinating polyradiculoneuropathy — COMPLETED · PHASE3
• Intravenous immunoglobulin overtreatment in CIDP — ACTIVE_NOT_RECRUITING · PHASE4
• A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy — TERMINATED · PHASE3
• An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy — NOT_YET_RECRUITING · PHASE1
• A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) — COMPLETED · PHASE3
• A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy — NOT_YET_RECRUITING · PHASE2
• Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial — ACTIVE_NOT_RECRUITING · NA
• Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing — COMPLETED
• Tongji NADs Cohort — NOT_YET_RECRUITING
• Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — COMPLETED · PHASE2
• A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) — OTHER · PHASE2
• Role of High Frequency Ultrasound in Demyelinating Polyneuropathies — COMPLETED
• Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. — NOT_YET_RECRUITING · PHASE1
• Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP — COMPLETED · PHASE3
• Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases (CIDP Echo-nerf) — WITHDRAWN
• Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy — OTHER · NA
• A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy — COMPLETED · PHASE2
• A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — COMPLETED · PHASE3
• A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — COMPLETED
• A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy — COMPLETED · PHASE2
• Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin — COMPLETED · NA
• InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy — WITHDRAWN · NA
• Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy — COMPLETED
• The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies — COMPLETED · PHASE2
• Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 — TERMINATED · PHASE3
• Efficacy and Safety Study of I10E in Treatment of Patients With CIDP — COMPLETED · PHASE3
• Transcriptome Analysis of the Peripheral Blood in CIDP — OTHER · NA
• Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. — COMPLETED · PHASE3
• Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP — TERMINATED · PHASE2
• MRI in Diagnosing and Monitoring CIDP — COMPLETED
• Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — COMPLETED · PHASE2

Refine this search